bluebird bio, Inc. (NASDAQ:BLUE) insider Eric Sullivan sold 861 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $93.83, for a total transaction of $80,787.63. Following the completion of the sale, the insider now directly owns 5,924 shares in the company, valued at $555,848.92. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Eric Sullivan also recently made the following trade(s):

  • On Thursday, June 29th, Eric Sullivan sold 6,787 shares of bluebird bio stock. The shares were sold at an average price of $108.96, for a total transaction of $739,511.52.

bluebird bio, Inc. (NASDAQ:BLUE) opened at 98.65 on Tuesday. The firm’s 50 day moving average is $102.86 and its 200-day moving average is $88.98. The firm’s market cap is $4.49 billion. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $123.75.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.66) by $0.07. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. During the same period last year, the firm earned ($1.59) EPS. The business’s revenue for the quarter was up 977.4% on a year-over-year basis. On average, equities analysts forecast that bluebird bio, Inc. will post ($6.69) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/08/bluebird-bio-inc-nasdaqblue-insider-sells-80787-63-in-stock.html.

Hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can raised its stake in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares during the period. Turner Investments LLC acquired a new stake in bluebird bio during the second quarter valued at about $184,000. SG Americas Securities LLC raised its stake in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 295 shares during the period. Affinity Investment Advisors LLC acquired a new stake in bluebird bio during the second quarter valued at about $246,000. Finally, Trexquant Investment LP acquired a new stake in bluebird bio during the second quarter valued at about $294,000.

A number of brokerages have recently issued reports on BLUE. Sanford C. Bernstein began coverage on shares of bluebird bio in a report on Thursday, July 27th. They issued a “market perform” rating and a $109.00 target price on the stock. BMO Capital Markets reaffirmed a “buy” rating and issued a $108.00 target price on shares of bluebird bio in a report on Friday. Cantor Fitzgerald set a $39.00 price target on shares of bluebird bio and gave the company a “sell” rating in a report on Saturday, June 24th. Morgan Stanley increased their price target on shares of bluebird bio from $103.00 to $105.00 and gave the company an “equal weight” rating in a report on Monday. Finally, Cowen and Company reissued an “outperform” rating on shares of bluebird bio in a report on Friday, June 9th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. bluebird bio currently has a consensus rating of “Hold” and an average price target of $100.66.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.